1 Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123, 465-472, doi:10.1007/s00401-011-0922-z (2012).
2 Kool, M. et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123, 473-484, doi:10.1007/s00401-012-0958-8 (2012).
3 Forget, A. et al. Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell 34, 379-395 e377, doi:10.1016/j.ccell.2018.08.002 (2018).
4 Ramaswamy, V. et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol, doi:10.1007/s00401-016-1569-6 (2016).
5 Cho, Y. J. et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29, 1424-1430, doi:10.1200/JCO.2010.28.5148 (2011).
6 Cavalli, F. M. G. et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 31, 737-754 e736, doi:10.1016/j.ccell.2017.05.005 (2017).
7 Bandopadhayay, P. et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 20, 912-925, doi:10.1158/1078-0432.CCR-13-2281 (2014).
8 Hill, R. M. et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 27, 72-84, doi:10.1016/j.ccell.2014.11.002 (2015).
9 Ecker, J. et al. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun 3, 22, doi:10.1186/s40478-015-0201-7 (2015).
10 Gottardo, N. G. et al. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol 127, 189-201, doi:10.1007/s00401-013-1213-7 (2014).
11 Archer, T. C. et al. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 34, 396-410 e398, doi:10.1016/j.ccell.2018.08.004 (2018).
12 Zomerman, W. W. et al. Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. Cell Rep 22, 3206-3216, doi:10.1016/j.celrep.2018.02.089 (2018).
13 Grabowski, P. Alternative splicing takes shape during neuronal development. Curr Opin Genet Dev 21, 388-394, doi:10.1016/j.gde.2011.03.005 (2011).
14 Miura, P., Shenker, S., Andreu-Agullo, C., Westholm, J. O. & Lai, E. C. Widespread and extensive lengthening of 3' UTRs in the mammalian brain. Genome Res 23, 812-825, doi:10.1101/gr.146886.112 (2013).
15 Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470-476, doi:10.1038/nature07509 (2008).
16 Xu, Q., Modrek, B. & Lee, C. Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res 30, 3754-3766 (2002).
17 Yeo, G. W., Van Nostrand, E., Holste, D., Poggio, T. & Burge, C. B. Identification and analysis of alternative splicing events conserved in human and mouse. Proc Natl Acad Sci U S A 102, 2850-2855, doi:10.1073/pnas.0409742102 (2005).
18 Sakakibara, S. et al. Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol 176, 230-242 (1996).
19 Sakakibara, S. & Okano, H. Expression of neural RNA-binding proteins in the postnatal CNS: implications of their roles in neuronal and glial cell development. J Neurosci 17, 8300-8312 (1997).
20 Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526, doi:10.1038/nature11287 (2012).
21 Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumor growth by clonal analysis. Nature 488, 527-530, doi:10.1038/nature11344 (2012).
22 Schepers, A. G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730-735, doi:10.1126/science.1224676 (2012).
23 Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100, 15178-15183, doi:10.1073/pnas.2036535100 (2003).
24 Singh, S., Clarke, I., Terasaki, M. & Bonn, V. Identification of a cancer stem cell in human brain tumors. Cancer Research (2003).
25 Singh, S. K. et al. Identification of human brain tumor initiating cells. Nature 432, 396-401, doi:10.1038/nature03128 (2004).
26 Kanemura, Y. et al. Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 68, 141-152 (2001).
27 Toda, M. et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 34, 1-7 (2001).
28 Sanchez-Diaz, P. C., Burton, T. L., Burns, S. C., Hung, J. Y. & Penalva, L. O. Musashi1 modulates cell proliferation genes in the medulloblastoma cell line Daoy. BMC Cancer 8, 280, doi:10.1186/1471-2407-8-280 (2008).
29 Chen, H. Y. et al. Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma. Oncotarget 7, 42485-42501, doi:10.18632/oncotarget.9890 (2016).
30 Cox, J. L. et al. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One 8, e62857, doi:10.1371/journal.pone.0062857 (2013).
31 Dahlrot, R. H. et al. Prognostic value of Musashi-1 in gliomas. J Neurooncol 115, 453-461, doi:10.1007/s11060-013-1246-8 (2013).
32 Dahlrot, R. H. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dan Med J 61, B4944 (2014).
33 de Araujo, P. R. et al. Musashi1 Impacts Radio-Resistance in Glioblastoma by Controlling DNA-Protein Kinase Catalytic Subunit. Am J Pathol 186, 2271-2278, doi:10.1016/j.ajpath.2016.05.020 (2016).
34 Johannessen, T. C. et al. Highly infiltrative brain tumors show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Appl Neurobiol 35, 380-393, doi:10.1111/j.1365-2990.2008.01008.x (2009).
35 Lagadec, C. et al. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells 32, 135-144, doi:10.1002/stem.1537 (2014).
36 Muto, J. et al. RNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of Notch and PI3 kinase/Akt signaling pathways. PLoS One 7, e33431, doi:10.1371/journal.pone.0033431 (2012).
37 Vo, D. T. et al. The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol 181, 1762-1772, doi:10.1016/j.ajpath.2012.07.031 (2012).
38 Vo, D. T. et al. The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol 8, 817-828, doi:10.4161/rna.8.5.16041 (2011).
39 Vo, D. T. et al. The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res 10, 143-155, doi:10.1158/1541-7786.MCR-11-0208 (2012).
40 Uren, P. J. et al. RNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma. Mol Cell Biol 35, 2965-2978, doi:10.1128/MCB.00410-15 (2015).
41 Potten, C. S. et al. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation 71, 28-41, doi:10.1046/j.1432-0436.2003.700603.x (2003).
42 Li, D. et al. Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer. Ann Surg Oncol 18, 2074-2083, doi:10.1245/s10434-011-1567-9 (2011).
43 Van Nostrand, E. L. et al. Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP). Nat Methods 13, 508-514, doi:10.1038/nmeth.3810 (2016).
44 Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760, doi:10.1038/nature05236 (2006).
45 Lin, J. C. et al. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties. Radiother Oncol, doi:10.1016/j.radonc.2018.09.014 (2018).
46 Chen, H. Y. et al. Musashi-1 promotes chemoresistant granule formation by PKR/eIF2alpha signalling cascade in refractory glioblastoma. Biochim Biophys Acta 1864, 1850-1861, doi:10.1016/j.bbadis.2018.02.017 (2018).
47 Panosyan, E. H. et al. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatric Blood & Cancer 55, 644-651, doi:10.1002/pbc.22627 (2010).
48 Kanai, R. et al. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther 13, 106-116, doi:10.1038/sj.gt.3302636 (2006).
49 Kagara, N. et al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am J Pathol 181, 257-267, doi:10.1016/j.ajpath.2012.03.019 (2012).
50 Yi, C. et al. Luteolin inhibits Musashi1 binding to RNA and disrupts cancer phenotypes in glioblastoma cells. RNA Biol 15, 1420-1432, doi:10.1080/15476286.2018.1539607 (2018).
51 Lan, L. et al. Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins. BMC Cancer 18, 809, doi:10.1186/s12885-018-4704-z (2018).
52 Velasco, M. X. et al. Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development. RNA 25, 768-782, doi:10.1261/rna.069211.118 (2019).
53 Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A. & van Lohuizen, M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397, 164-168, doi:10.1038/16476 (1999).
54 Jacobs, J. J. et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13, 2678-2690, doi:10.1101/gad.13.20.2678 (1999).
55 Leung, C. et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428, 337-341, doi:10.1038/nature02385 (2004).
56 Toledo, C. M. et al. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep 13, 2425-2439, doi:10.1016/j.celrep.2015.11.021 (2015).
57 Sakakibara, S. et al. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc Natl Acad Sci U S A 99, 15194-15199, doi:10.1073/pnas.232087499 (2002).
58 Pei, Y. et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 21, 155-167, doi:10.1016/j.ccr.2011.12.021 (2012).
59 Fox, R. G. et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature 534, 407-411, doi:10.1038/nature17988 (2016).
60 Li, Y., Choi, P. S., Casey, S. C. & Felsher, D. W. Activation of Cre recombinase alone can induce complete tumor regression. PLoS One 9, e107589, doi:10.1371/journal.pone.0107589 (2014).
61 McFarland, J. M. et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun 9, 4610, doi:10.1038/s41467-018-06916-5 (2018).
62 Ohyama, T. et al. Structure of Musashi1 in a complex with target RNA: the role of aromatic stacking interactions. Nucleic Acids Res 40, 3218-3231, doi:10.1093/nar/gkr1139 (2012).
63 Northcott, P. A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49-56, doi:10.1038/nature11327 (2012).
64 Kool, M. et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3, e3088, doi:10.1371/journal.pone.0003088 (2008).
65 Ferrucci, V. et al. Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-beta-OTX2-SNAIL via PTEN inhibition. Brain 141, 1300-1319, doi:10.1093/brain/awy039 (2018).
66 McCarthy, D. J. & Smyth, G. K. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics 25, 765-771, doi:10.1093/bioinformatics/btp053 (2009).
67 Northcott, P. A. et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29, 1408-1414, doi:10.1200/JCO.2009.27.4324 (2011).
68 Northcott, P. A. et al. The whole-genome landscape of medulloblastoma subtypes. Nature 547, 311-317, doi:10.1038/nature22973 (2017).
69 Baltz, A. G. et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol Cell 46, 674-690, doi:10.1016/j.molcel.2012.05.021 (2012).
70 Castello, A. et al. System-wide identification of RNA-binding proteins by interactome capture. Nat Protoc 8, 491-500, doi:10.1038/nprot.2013.020 (2013).
71 Keene, J. D. & Tenenbaum, S. A. Eukaryotic mRNPs may represent posttranscriptional operons. Mol Cell 9, 1161-1167, doi:10.1016/s1097-2765(02)00559-2 (2002).
72 Doma, M. K. & Parker, R. Endonucleolytic cleavage of eukaryotic mRNAs with stalls in translation elongation. Nature 440, 561-564, doi:10.1038/nature04530 (2006).
73 Frischmeyer, P. A. et al. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 295, 2258-2261, doi:10.1126/science.1067338 (2002).
74 Schmidt, E. K., Clavarino, G., Ceppi, M. & Pierre, P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods 6, 275-277, doi:10.1038/nmeth.1314 (2009).
75 Lavallee-Adam, M., Rauniyar, N., McClatchy, D. B. & Yates, J. R., 3rd. PSEA-Quant: a protein set enrichment analysis on label-free and label-based protein quantification data. J Proteome Res 13, 5496-5509, doi:10.1021/pr500473n (2014).
76 Kolde, R., Laur, S., Adler, P. & Vilo, J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics 28, 573-580, doi:10.1093/bioinformatics/btr709 (2012).
77 Futreal, P. A. et al. A census of human cancer genes. Nat Rev Cancer 4, 177-183, doi:10.1038/nrc1299 (2004).
78 Jones, D. T. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100-105, doi:10.1038/nature11284 (2012).
79 Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106-110, doi:10.1038/nature11329 (2012).
80 Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439, doi:10.1126/science.1198056 (2011).
81 Northcott, P. A. et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 123, 615-626, doi:10.1007/s00401-011-0899-7 (2012).
82 Pomeroy, S. L. et al. Prediction of central nervous system embryonal tumor outcome based on gene expression. Nature 415, 436-442, doi:10.1038/415436a (2002).
83 Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48, doi:10.1038/nature11213 (2012).
84 Bowman, R. L., Wang, Q., Carro, A., Verhaak, R. G. & Squatrito, M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol 19, 139-141, doi:10.1093/neuonc/now247 (2017).
85 Wu, G. & Haw, R. Functional Interaction Network Construction and Analysis for Disease Discovery. Methods Mol Biol 1558, 235-253, doi:10.1007/978-1-4939-6783-4_11 (2017).
86 Reimand, J. et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc 14, 482-517, doi:10.1038/s41596-018-0103-9 (2019).
87 Paczkowska, M. et al. Integrative pathway enrichment analysis of multivariate omics data. BbioRxiv, doi:https://doi.org/10.1101/399113 (2018).
88 Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337-342, doi:10.1038/nature10098 (2011).
89 Vogel, C. et al. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol 6, 400, doi:10.1038/msb.2010.59 (2010).
90 Castello, A. et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149, 1393-1406, doi:10.1016/j.cell.2012.04.031 (2012).
91 Fan, X. et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 64, 7787-7793, doi:10.1158/0008-5472.CAN-04-1446 (2004).
92 Garzia, L. et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 4, e4998, doi:10.1371/journal.pone.0004998 (2009).
93 Zhong, W., Feder, J. N., Jiang, M. M., Jan, L. Y. & Jan, Y. N. Asymmetric localization of a mammalian numb homolog during mouse cortical neurogenesis. Neuron 17, 43-53, doi:10.1016/s0896-6273(00)80279-2 (1996).
94 Qin, H. et al. A novel transmembrane protein recruits numb to the plasma membrane during asymmetric cell division. J Biol Chem 279, 11304-11312, doi:10.1074/jbc.M311733200 (2004).
95 Petersen, P. H., Zou, K., Hwang, J. K., Jan, Y. N. & Zhong, W. Progenitor cell maintenance requires numb and numblike during mouse neurogenesis. Nature 419, 929-934, doi:10.1038/nature01124 (2002).
96 Petersen, P. H., Zou, K., Krauss, S. & Zhong, W. Continuing role for mouse Numb and Numbl in maintaining progenitor cells during cortical neurogenesis. Nat Neurosci 7, 803-811, doi:10.1038/nn1289 (2004).
97 Rasin, M. R. et al. Numb and Numbl are required for maintenance of cadherin-based adhesion and polarity of neural progenitors. Nat Neurosci 10, 819-827, doi:10.1038/nn1924 (2007).
98 Imai, T. et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol 21, 3888-3900, doi:10.1128/MCB.21.12.3888-3900.2001 (2001).
99 Zearfoss, N. R. et al. A conserved three-nucleotide core motif defines Musashi RNA binding specificity. J Biol Chem 289, 35530-35541, doi:10.1074/jbc.M114.597112 (2014).
100 Rentas, S. et al. Musashi-2 attenuates AHR signalling to expand human haematopoietic stem cells. Nature 532, 508-511, doi:10.1038/nature17665 (2016).
101 Hashimoto, K. & Tsuji, Y. Arsenic-Induced Activation of the Homeodomain-Interacting Protein Kinase 2 (HIPK2) to cAMP-Response Element Binding Protein (CREB) Axis. J Mol Biol 429, 64-78, doi:10.1016/j.jmb.2016.11.015 (2017).
102 Blough, R. I. et al. Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. Am J Med Genet 90, 29-34 (2000).
103 Bourdeaut, F. et al. Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatr Blood Cancer 61, 383-386, doi:10.1002/pbc.24765 (2014).
104 Zhang, J. et al. Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons. Nat Neurosci 10, 77-86, doi:10.1038/nn1816 (2007).
105 Chalazonitis, A. et al. Homeodomain interacting protein kinase 2 regulates postnatal development of enteric dopaminergic neurons and glia via BMP signaling. J Neurosci 31, 13746-13757, doi:10.1523/JNEUROSCI.1078-11.2011 (2011).
106 Kondo, S. et al. Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci U S A 100, 5431-5436, doi:10.1073/pnas.0530308100 (2003).
107 Milde, T. et al. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J Neurooncol 110, 335-348, doi:10.1007/s11060-012-0978-1 (2012).
108 Subapanditha, M. K., Adile, A. A., Venugopal, C. & Singh, S. K. Flow Cytometric Analysis of Brain Tumor Stem Cells. Methods Mol Biol 1869, 69-77, doi:10.1007/978-1-4939-8805-1_6 (2019).
109 Robertson, D., Savage, K., Reis-Filho, J. S. & Isacke, C. M. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol 9, 13, doi:10.1186/1471-2121-9-13 (2008).
110 Hart, T. et al. Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens. G3 (Bethesda) 7, 2719-2727, doi:10.1534/g3.117.041277 (2017).
111 Mair, B. et al. High-throughput genome-wide phenotypic screening via immunomagnetic cell sorting. Nat Biomed Eng 3, 796-805, doi:10.1038/s41551-019-0454-8 (2019).
112 Lamb, J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7, 54-60, doi:10.1038/nrc2044 (2007).
113 Smirnov, P. et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics 32, 1244-1246, doi:10.1093/bioinformatics/btv723 (2016).
114 Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med 23, 405-408, doi:10.1038/nm.4306 (2017).
115 van Nostrand, E. L., Freese P, Pratt GA, Wang X, Wei X, Xiao R, Blue SM, Chen J-Y, Cody NAL, Dominguez D, Olsen S, Sundararaman B, Zhan L, Bazile C, Bouvrette LPB, Bergalet J, Duff MO,Garcia KE, Gelboin-Burkhart C, Hochman M, Lambert NJ, Li H, Nguyen TB, Palden T, Rabano I, Sathe S, Stanton R, Su A, Wang R, Yee BA, Zhou B, Louie AL, Aigner S, Fu X-D, Lecuyer E, Burge CB, Graveley BR, Yeo GW. A Large-Scale Binding and Functional Map of Human RNA Binding Proteins. bioRxiv, doi:https://doi.org/10.1101/179648 (2018).
116 Lovci, M. T. et al. Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nat Struct Mol Biol 20, 1434-1442, doi:10.1038/nsmb.2699 (2013).
117 Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26, 1367-1372, doi:10.1038/nbt.1511 (2008).
118 Vizcaino, J. A. et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res 44, 11033, doi:10.1093/nar/gkw880 (2016).
119 Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550, doi:10.1073/pnas.0506580102 (2005).
120 Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128, doi:10.1186/1471-2105-14-128 (2013).
121 Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90-97, doi:10.1093/nar/gkw377 (2016).
122 P'ng, C. et al. BPG: Seamless, automated and interactive visualization of scientific data. BMC Bioinformatics 20, 42, doi:10.1186/s12859-019-2610-2 (2019).
123 Wickham, H. ggplot2: elegant graphics for data analysis. 2nd edn, (Springer International Piublishing, 2016).